期刊文献+

用于治疗前列腺癌的卡巴他赛递药系统研究进展

Research advances in drug delivery system of cabazitaxel for treatment of patients with prostate cancer
下载PDF
导出
摘要 卡巴他赛是一种新型紫杉烷类抗肿瘤药物,对于多西他赛治疗无效的、激素难治性、转移性前列腺癌患者效果显著。虽然作为临床二线用药,但由于卡巴他赛对P-糖蛋白的低黏附性以及良好的药动学特性,使其具有较大的应用潜力,近年来越来越受到研究者们的关注。本文结合国内外研究进展,以卡巴他赛的药理作用、不良反应为出发点,对其用于前列腺癌治疗的递药系统研究进行综述。 Cabazitaxel is a new taxane-based anti-tumor drug, which has a significant effect on hormone refractory metastatic prostate cancer patients who are ineffective to docetaxel. Although cabazitaxel is used as a second-line clinical drug, it has great application potential due to its low adhesion to P-glycoprotein and good pharmacokinetic characteristics. In recent years, researchers are paying more attention to it. Based on the research progress achieved both at home and abroad and with the pharmacological effects and adverse drug reactions as the starting point, a comprehensive review was made in the drug delivery system of cabazitaxel for treatment of prostate cancer.
作者 万众 孙治国 鲁莹 王林辉 WAN Zhong;SUN Zhiguo;LU Ying;WANG Linhui(Department of Urology, Changzheng Hospital, Navy Military Medical University, Shanghai 200003,China;Teaching and Research Section of Pharmaceutics, School of Pharmacy, Navy Military Medical University, Shanghai 200433,China)
出处 《药学服务与研究》 CAS 2019年第2期121-124,共4页 Pharmaceutical Care and Research
关键词 卡巴他赛 前列腺癌 递药系统 药理作用 药物副反应报告系统 综述 cabazitaxel prostate cancer drug delivery system pharmacological effects adverse drug reactions reporting system review
  • 引文网络
  • 相关文献

参考文献10

二级参考文献69

  • 1叶定伟.前列腺癌的流行病学和中国的发病趋势[J].中华外科杂志,2006,44(6):362-364. 被引量:168
  • 2孙忠全.关于激素非依赖性前列腺癌的几点思考[J].老年医学与保健,2007,13(3):141-143. 被引量:1
  • 3HWANG C. Overcoming docetaxel resistance in prostate cancer: a perspective review[J]. Ther Adv Med Oncol , 2012,4(6):329-340.
  • 4MITA AC, DENIS LJ, ROWINSKY EK, et al. Phase Ⅰ and phar- macokinetic study of XRP6258 (RPR 116258A) , a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors [ J 1. Clin Cancer Res ,2009,15 (2) :723 - 730.
  • 5PIVOT X, KORALEWSKI P, HIDALGO JL,et al. A muhicenter phase Ⅱ study of XRP6258 administered as a 1-h i. v. infusion ev- ery 3 weeks in taxane-resistant metastatic breast cancer patients [J]. Ann Oncol, 2008,19(9) :1547 - 1552.
  • 6DE BONO JS, OUDARD S, OZGUROGLU M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxe! treatment: a randomised open-label trial [ J ]. Lancet, 2010,376 ( 9747 ) : 1147 - 1154.
  • 7BECZE E. Manage side effects of cabazitaxel in patients with castrate- resistant prostate cancer[ J]. ONS Connect, 2012,27(9) :16 -17.
  • 8Cabazitaxet at 20 mg'm 2 compared to 25 mg'm 2 with predni- sone for the treatment of metastatic castration resistant prostate cancer(PROSELICA) [ EB/OL ]. http ://www. clinicahrials, gov/ et2/results? term = eabazitaxel&Search.
  • 9VILLANUEVA C, AWADA A, CAMPONE M,et al. A multicen- tre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer pro- gressing after anthracycline and taxane treatment: a phase Ⅰ/Ⅱ study[J]. Eur JCancer, 2011, 47(7) :1037-1045.
  • 10Thakkar H, Sharma RK, Mishra AK, et al. Albumin Microspheres as Carriers for the Antiarthritic Drug Celecoxib [ J ]. AAPS Pharm- SciTech,2005,6( 1 ) :65 -73.

共引文献332

;
使用帮助 返回顶部